Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Dec
28
Today In Oncology
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo